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Abstract
Transgenic C57BL/6 mice expressing human serum amyloid P component (HuSAP) are resistant to Shiga toxin 2 (Stx2) at
dosages that are lethal in HuSAP-negative wild-type mice. However, it is well established that Stx2 initiates extra-intestinal
complications such as the haemolytic-uremic syndrome despite the presence of HuSAP in human sera. We now
demonstrate that co-administering purified Escherichia coli O55 lipopolysaccharide (LPS), at a dosage of 300 ng/g body
weight, to HuSAP-transgenic mice increases their susceptibility to the lethal effects of Stx2. The enhanced susceptibility to
Stx2 correlated with an increased expression of genes encoding the pro-inflammatory cytokine TNFa and chemokines of the
CXC and CC families in the kidneys of LPS-treated mice, 48 hours after the Stx2/LPS challenge. Co-administering the
glucocorticoid dexamethasone, but not the LPS neutralizing cationic peptide LL-37, protected LPS-sensitized HuSAP-
transgenic mice from lethal doses of Stx2. Dexamethasone protection was specifically associated with decreased expression
of the same inflammatory mediators (CXC and CC-type chemokines and TNFa) linked to enhanced susceptibility caused by
LPS. The studies reveal further details about the complex cascade of host-related events that are initiated by Stx2 as well as
establish a new animal model system in which to investigate strategies for diminishing serious Stx2-mediated complications
in humans infected with enterohemorrhagic E. coli strains.
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Introduction
Haemolytic-uremic syndrome (HUS) is characterized by a triad
of clinical signs including thrombocytopenia, microangiopathic
haemolytic anaemia, and acute renal failure. Typically, HUS
occurs in young children as a consequence of an infection by
enterohemorrhagic Escherichia coli (EHEC) strains, including, but
not limited to, O157:H7 serotype strains. HUS is generally
thought to be initiated when the Shiga toxins, which are expressed
by EHEC, cause injury to endothelial cells lining the glomerular
capillaries. Although Shiga toxin 2 (Stx2) is more commonly
associated with HUS than Stx1 [1,2], immunoglobulin-depleted
human serum possesses an innate ability to neutralize the cytotoxic
activity of Stx2 [3]. The factor responsible for this neutralizing
activity was identified by Kimura et al. as human serum amyloid P
component (HuSAP) [4].
HuSAP is a member of the pentraxin protein family and acts as
a soluble pattern recognition molecule which interacts with altered
self-antigens and conserved microbial components subsequently
targeting these for catabolic disposal via the reticuloendothelial
system [5,6]. We previously demonstrated that HuSAP also
inhibits Stx2 from binding its cellular receptor, the glycolipid
globotriaosylceramide (Gb3) [7]. This activity is apparently unique
to HuSAP, since serum from a variety of other species, including
mice, fails to neutralize Stx2 [4]. We further demonstrated that
exogenous or endogenous HuSAP protects mice challenged with
purified Stx2 [8]. In contrast, we also showed that the initial toxin-
mediated renal damage in humans can occur despite the presence
of normal concentrations of HuSAP in their sera.
Although injecting purified Stx2 containing little LPS into mice
results in acute renal failure, one of the three clinical signs of HUS,
the renal pathology in mice is distinct from that observed in human
cases of HUS. However, injecting a low dose of E. coli O55 LPS,
along with a single lethal dose of Stx2, was reported to reproduce
many of the human signs of HUS in mice including neutrophilia,
increased serum creatinine and blood urea nitrogen (BUN) and most
notably, glomerular fibrin deposition and endothelial damage [9].
Interestingly, Gb3 is not expressed in the murine glomerulus and
Stx2 specifically damages the murine collecting duct epithelia in this
model [10].The reasonfor the glomerular damageobserved inLPS-
treated Stx2-challenged mice is therefore unclear; however similar
glomerular damage has also been observed when mice are injected
with multiple low doses of LPS-free Stx2, indicating that LPS is not
required to elicit such damage [11]. Regardless, many of the
immunological changes observed in EHEC-infected HUS patients
were also observed in mice receiving both LPS and purified Stx2.
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inflammatory response, suggesting that at least low-grade
endotoxemia may occur following EHEC infection, despite the
characteristic absence of fever [12]. HUS patients often exhibit a
systemic cytokine response with increased serum concentrations of
pro-inflammatory cytokines such as interleukin (IL)-8, IL-1b, IL-6
and, in some cases, tissue necrosis factor a (TNFa), as well as a
decline in anti-inflammatory cytokines [13,14,15,16,17,18]. The
presence of these cytokines has also been detected in urine of some
HUS patients, suggesting that a local inflammatory response in the
kidneys may occur as well [17,18,19]. These findings are
consistent with the observation of neutrophil activation and
accumulation in the glomeruli of children with HUS, and an
associated elevation in CXC chemokines such as growth-related
oncogene (CXCL1/GRO) and granulocyte colony stimulating
factor (G-CSF) [16,20,21]. Increased serum concentrations of
monocyte chemotactic protein 1 (CCL2/MCP-1), macrophage
inflammatory protein 1 (CCL4/MIP-1) and renal macrophage
infiltration have also been reported in humans [19,20]. These
chemokines appear to play an important role in pathology since
the level to which they are increased positively correlates with the
severity of the renal damage.
For the most part, the changes in cytokine and chemokine
concentrations in humans are reproduced in mice when LPS and
Stx2 are co-administered. The circulating concentrations of IL-6
and TNF-a increase dramatically immediately following injection
of Stx2 and LPS, as does the production of chemokines CCL2,
CCL3 (MIP-1), and CXCL1 in the murine kidney [9,22,23,24].
Coupled with increases in vascular cell adhesion molecule 1
(VCAM-1) and intercellular adhesion molecule 1 (ICAM-1), these
changes appear to facilitate the glomerular infiltration of
neutrophils and macrophages and contribute to the observed
renal damage [9,22,24]. Furthermore, Stx2 and LPS treatment
activates coagulation/fibrinogenesis pathways, as indicated by
increased plasma thrombin-antithrombin III (TAT) complex,
fibrinogen and plasminogen activator inhibitor-1(PAI-1) levels
and decreased platelet counts [9,23], all of which have also been
detected in human HUS patients [25,26,27]. The observation that
co-administering LPS and Stx2 shifted the spectrum of patholog-
ical changes in mice to one more closely resembling that observed
in HUS victims prompted us to investigate whether LPS would
also alter the susceptibility of HuSAP transgenic mice to Stx2 and
the results of these investigations are reported herein.
Methods
LPS-sensitized mouse Shigatoxemia model
All animal work was conducted according to the guidelines of
the Canadian Council on Animal Care with the approval of the
University of Calgary Health Sciences Animal Care Committee
(Protocol #M07054). The transgenic mice used for these
experiments were C57BL/6-Tg(APSC)1Imeg mice, which exhibit
liver-specific expression of HuSAP at a stable circulating serum
concentration of 30–40 mg/mL, similar to the concentration in
human serum. These mice were first created by Zhao et al. and
were bred in-house [28]. Stx2 was affinity purified using Synsorb-
P
K and residual LPS was removed using Endotrap blue LPS
affinity columns as described previously [29]. The concentration of
LPS in the purified Stx2 preparations was determined to be less
than 0.001 endotoxin units per mg protein as determined by the
colorimetric Limulus amebocyte lysate assay. Control wild-type
(WT) and transgenic HuSAP+ C57BL/6 mice (male and female,
age 8–10 weeks) were IP injected with 225 pg/g body weight (BW)
Stx2 alone, 300 ng/g BW of E. coli O55 LPS (Sigma-Aldrich)
alone, or both according to the protocol described by Keepers et al.
[9].
Five mL of blood was drawn from the tail vein prior to and
10 hours after the injections and diluted 1:8 in crystal violet
diluent (0.1 mg/mL crystal violet, 1% (v/v) acetic acid) to lyse red
blood cells and stain remaining leukocytes. White blood cells were
enumerated using a haemocytometer. Blood smears were also
prepared from these samples. These were methanol-fixed and then
Wright-Giemsa stained for differentiation of individual cell types
(HARLECO Hematology Stain, EMD Chemicals, Gibbstown,
New Jersey). Mice were euthanized by CO2 asphyxiation at the
onset of clear signs (lethargy) of Shigatoxemia and their kidneys
were removed and fixed overnight in 10% buffered (pH 7.2–7.4)
formalin prior to paraffin embedding. Four micron sections were
stained with hematoxylin and eosin (H&E), as well as periodic
acid-Schiff (PAS), and phosphotungstic acid-hematoxylin (PTAH).
Animals that had not succumbed to the effects of Stx2 by
120 hours were euthanized and their kidneys were removed for
light microscopy examination. Microscopic examination was
performed on sagittal sections of the kidney that included the
papilla, cortex and medulla. Histopathological changes were
described according to distribution, severity and morphological
features and were scored on a scale of 0–4 (0=no observable
abnormalities, 1=minimal or less than 10% of tissue affected;
2=Mild or 11 to 25% of tissue affected; 3=Moderate or 26 to
50% of tissue affected; 4=Severe or more than 50% of tissue
affected). The pathologist (CF) was unaware of the treatment
groups.
In a separate experiment, HuSAP-negative (WT) C57BL/6
mice (Charles River Laboratories International Inc., Wilmington,
Massachusetts) were IP injected with 6.3, 20, 63 or 200 pg/g BW
of Stx2 alone or Stx2 admixed with a constant 300 ng/g BW of
LPS.
Stx2 Vero cytotoxicity neutralization assay
Stx2 cytotoxicity in the presence and absence of HuSAP and
LPS was determined using the Vero cytotoxicity assay. HuSAP
(supplied by Dr. Mark Pepys, University College London, United
Kingdom) was incubated in 100 mL minimal essential medium
(MEM) at 20 mg/mL (or 3-fold serial dilutions beginning from
20 mg/mL) for 30 minutes at 37uC+5% CO2 either alone or
admixed with 3-fold serial dilutions of E. coli O55 LPS (starting
from 20 mg/mL). Stx2 (20 ng/mL) in 100 mL MEM+10% fetal
bovine serum (FBS) was then added and the mixture was
incubated for 1 h at 37uC+5% CO2, before the entire volume
(200 mL) was transferred to confluent Vero cell monolayers in 96
well tissue culture plates. The Vero cells were incubated for
2 hours and the media containing toxin was then removed. After
gently washing the monolayers with MEM two times, 200 mLo f
MEM+10% FBS was added and the cells were incubated at
37uC+5% CO2 for 72 hours. Surviving cells were fixed with 10%
methanol and Giemsa-stained and absorbance was measured to
assess Vero cell survival. To test the ability of LPS to inhibit
HuSAP-mediated neutralization of Stx2 in the presence of other
blood components such as LPS-binding protein, serial dilutions of
serum from a healthy human volunteer were incubated with Stx2
(20 ng/mL) for 1 h at 37uC+5% CO2 prior to adding to Vero cell
monolayers. Serum was incubated with or without LPS (100 mg/
mL) for 30 min prior to incubating with Stx2.
HuSAP-Stx2 ELISA
Stx2 binding to HuSAP in the presence and absence of LPS was
determined using a solid-phase ELISA-type binding assay.
Microtitre plates (Corning Incorporated, Lowell, Massachusetts)
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2 mg/mL in 10 mM Tris and 0.14 M NaCl, pH 8.0 buffer (TN
buffer) or TN buffer containing 2 mM CaCl2 (TC buffer) and then
thoroughly washed five times with TN or TC buffer before
blocking with 3% (w/v) bovine serum albumin (BSA – Thermo
Scientific, Waltham, Massachusetts) in TN or TC buffer. A
constant concentration of 20 mg/mL of HuSAP alone, or admixed
with 100 mg/mL LPS, in TN or TC buffer supplemented with 4%
(w/v) BSA (prevents non-specific aggregation of HuSAP, M. B.
Pepys, personal communication) was added to the 96 well
microtiter plates which were then incubated for an additional
1 h. The microtiter plates were again thoroughly washed (five
times with TN or TC buffer +4% BSA). Bound HuSAP was
detected using a 2000 fold dilution of polyclonal rabbit anti-
HuSAP antibody (Dako Canada Inc., Mississauga, Ontario)
followed by a 2000 fold dilution of monoclonal goat anti-rabbit
IgG antibody conjugated to horseradish peroxidase (Sigma-
Aldrich), both in TN or TC buffer. Peroxidase was detected using
the colourimetric 2,29-azino-bis(3-ethylbenzthiazoline-6-sulphonic
acid) reagent (ABTS, Sigma-Aldrich) in 50 mM sodium citrate
buffer (pH 4.2). Absorbance at 410 nm was recorded using a
SpectraMAX340 plate reader (Molecular Devices, Sunnyvale,
California) after 20 min development.
Inflammatory response to Stx2 and LPS
Mice (WT and HuSAP+) were IP injected with Stx2 (225 pg/g
BW) and/or LPS (300 ng/g BW). After 2 or 48 h, the mice were
euthanized by CO2 asphyxiation and blood was collected by
cardiac exsanguination into heparin-containing tubes. The kidneys
were removed and 30 mg portions were stored at 220uCi n
RNAlaterH solution (Applied Biosystems, Austin, Texas). RNA was
purified from stored tissue using the RNeasy Mini Kit using the
protocol recommended by the manufacturer (Qiagen Inc.
Valencia, California). Tissue was homogenized in lysis buffer
using a Polytron 1300D homogenizer and tissue debris was
subsequently removed by centrifugation. RNA was eluted from the
column in RNAse-free water and, to ensure accuracy in the
detection of potentially low copy mRNA transcripts, genomic
DNA was removed with the DNA-free
TM kit (DNAse I digestion)
according to the manufacturer’s instructions (Ambion, Austin, TX,
USA). Purified RNA was used to generate cDNA using the First
Strand Synthesis kit (Invitrogen). Briefly, cDNA was generated
from 1 mg of RNA by reverse transcription using oligo(dT)20
primers and SuperScript
TM II Reverse Transcriptase (RT). The
remaining RNA was degraded using RNAse H.
Expression of pro-inflammatory cytokine, chemoattractant and
coagulation factor genes was assessed by quantitative real-time
PCR (qPCR) of various targets which were selected for analysis
based on the results of previous studies [9,22,23,24] where Stx2
and LPS were co-administered to WT mice, or based on their
reported role in the development of HUS in EHEC-infected
human subjects. The primers used for amplification and
references for each selected gene are summarized in Table S1.
Primers were first tested using traditional PCR and gel
electrophoresis to ensure each primer set yielded a single product
and gradient PCR was performed as required to identify suitable
annealing temperatures. qPCR analysis was performed using an
iQ5
TM thermal cycler (Bio-Rad, Hercules, CA, USA) in 12.5 mL
reactions using Maxima
TM SYBR Green qPCR mix (Fermentas,
Burlington, ON, Canada). Expression was normalized to the
reference genes a-actin (Actb) and glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) by modifying the denominator of the Pfaffl
equation which takes into account the relative efficiency of each
primer pair [30]. PCR efficiency was calculated by a limiting
dilution experiment, in which five 10-fold serial dilutions were
examined (Table S1). Melting curves were performed on all
qPCR reactions to ensure specific products were generated and
all samples with incorrect or multiple peaks were not analyzed
further. Each mouse cDNA sample was analyzed for each gene in
triplicate to account for template loading and amplification
inconsistencies. The quantification cycles in triplicate were
averaged for each mouse and compared to the no treatment
group to determine a relative fold change in gene expression. The
relative fold increase in gene expression was then averaged within
each group with standard deviation indicating the variation
between the three mice.
Serum IL-6 concentrations in Stx2-challenged LPS-treated
mice were determined using the OptEIA capture ELISA (BD
Biosciences) method. 96 well microtitre plates were coated
overnight with a 250-fold dilution of anti-mouse IL-6 capture
antibodies in PBS. The microtiter plates were washed three
times with PBST and then blocked for two hours with PBS+10%
FBS. The microtiter plates were again washed three times with
PBST. Two-fold serial dilutions of mouse serum samples, as well
as recombinant mouse IL-6 standards, were prepared in
PBS+10% FBS and added to the microtiter plates. After two
hours, the plates were thoroughly washed seven times. A 250-
fold dilution (in PBS+10% FBS) of biotinylated anti-mouse IL-6
detecting antibodies was added and the microtiter plates were
incubated for 1 h. The plates were again washed five times and
a 250-fold dilution (in PBS+10% FBS) of avidin-HRP detecting
reagent was added. The microtiter plates were incubated for
1 h, washed five times with PBST, and bound HRP was
detected with ABTS reagent as previously described. Except for
the anti-IL-6 coating step, which was performed at 4uC, all
incubations were performed at 37uC. The resulting absorbance
measurements were used to calculate the concentration of each
cytokine in the initial serum samples by comparing to the
standard curve generated using known concentrations of
recombinant IL-6.
Suppression of immune response and protection from
Stx2/LPS challenge
Two compounds were tested for their ability to prevent the
predominantly-LPS mediated inflammatory response in Hu-
SAP+ mice and restore their resistance to Stx2. LL-37, a human
cathelicidin-derived antimicrobial peptide, binds LPS with high
affinity and prevents it from binding LPS binding protein and
thereby activating immune cells [31]. In addition to this direct
anti-endotoxin effect, LL-37 is able to modulate Toll-like
receptor activation and pro-inflammatory gene transcription.
Dexamethasone (DEX – Sigma-Aldrich Canada) is an anti-
inflammatory glucocorticoid and has been shown previously to
suppress the immune response to LPS [32,33] and to provide
some protection against Stx2 challenge [34]. For LL-37,
HuSAP+ mice were IP injected with 225 pg/g BW Stx2 and
300 ng/g BW LPS either alone or admixed with 0.5 or 5.0 mg/g
BW LL-37. For DEX, HuSAP+ or WT mice were subcutane-
ously injected with 2.5 mg/g BW DEX or control saline
30 minutes prior to the IP injection of Stx2 and LPS, according
to a previously published protocol for LPS neutralization [32].
Mice were weighed and monitored for signs of Shigatoxemia
over a period of 150 h. In a separate experiment, HuSAP+ mice
were euthanized by CO2 asphyxiation and exsanguinated by
cardiac puncture at 2 and 48 h for assessment of gene
expression and serum cytokine concentrations as described in
the previous section.
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LPS sensitizes HuSAP+ mice to Stx2
As shown in Figure 1A, and consistent with our previous
observations [8], HuSAP+ C57BL/6 transgenic mice are com-
pletely resistant to 225 pg/g BW purified Stx2, in contrast to WT
mice which were completely sensitive (compare red dashed with
solid red lines, Figure 1A, Log Rank/Mantel-Cox test p,0.001).
However, injecting LPS in addition to Stx2 reversed the protective
effect of HuSAP in these mice (black dashed line, Figure 1A). Like
WT mice, HuSAP+ mice lost 5–10% of their initial body weight
immediately (within 24 hours) following Stx2/LPS injection and
all eventually succumbed to the combined challenge (Figure 1A,
1B). Importantly, none of the mice injected with LPS alone
succumbed and minimal renal histological changes were detected
in these animals (Figures 1 and 2).
HuSAP may still offer some protection since the average
survival time (88.9+/210.9 h) of the HuSAP+ mice challenged
with Stx2 plus LPS was significantly (average time of death -
Student’s t-test p,0.001, Log Rank test p,0.001) longer relative
to WT mice challenged with Stx2 plus LPS (70.1+/212.4 h).
However, the histological alterations observed in the kidneys of the
mice at the time of euthanasia were generally more severe in
HuSAP+ mice which received Stx2/LPS relative to WT mice
which received the same treatment (Figure 2A). Consistent with
the report by Keepers et al. [9], mice that received Stx2 plus LPS
also exhibited greater signs, relative to mice receiving Stx2 alone,
of neutrophilia and lymphocytopenia, two clinical signs charac-
teristic of HUS, (Figure 2E and 2F) ten hours after toxin injection.
These changes appeared to be mediated predominantly by LPS,
since they occurred to a similar degree when LPS was injected
alone. None of these symptoms were prevented or lessened by
HuSAP. Therefore, despite its reported interaction with LPS [35],
we found no evidence that HuSAP antagonizes LPS action in
HuSAP+ C57BL/6 mice.
The histological appearance of renal tissue obtained from
representative mice at the time of euthanasia, or from the survivors
at 120 h, was generally consistent with the survival and weight loss
observations (Figure 2A–D). Lesions were more severe in mice
which received both Stx2 and LPS relative to those that received
Stx2 alone. Histological examination revealed no obvious
differences between the kidneys of mice treated with LPS alone
Figure 1. Survival and weight loss of HuSAP+ and WT mice following Stx2 and LPS challenge. HuSAP+ (dashed lines) mice and their WT
littermates (solid lines) received one of three treatments. Mice were IP injected with 225 pg/g BW Stx2 in combination with 300 ng/g BW E. coli
O55:H5 lipopolysaccharide (black lines), 225 pg/g Stx2 alone (red lines), or 300 ng/g LPS alone (green lines). The number of animals in each group is
listed beside each label. Animals were monitored every 2–4 hours, a representative group was weighed daily (B). Mice were euthanized by CO2
asphyxia if clear signs of lethargy were observed (A). The differences in survival between HuSAP+ that received Stx2 and those that received Stx2 and
LPS was statistically significant (Log Rank test p,0.001). The difference in survival between HuSAP+ and WT mice were statistically significant (Log
Rank test p,0.05) only in the absence of LPS.
doi:10.1371/journal.pone.0021457.g001
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mice at the time of euthanasia as a result of Shigatoxemia or at 120 hours and were fixed in formalin before paraffin embedding and H&E staining.
Consistent morphologic changes were restricted to the tubules in all groups and the severity of the tubular degeneration was scored and the results
within each group averaged (A). In mice treated with Stx2 and LPS, the predominant changes in morphology were moderate tubular degeneration
and dilatation (solid black arrows) with clear evidence of individual cell necrosis. The images presented are 406magnification and are representative
of the changes observed in all WT (B) and HuSAP+ (C) mice that were injected with Stx2 and LPS. A renal section from an untreated mouse is
presented for comparison (D). The circulating lymphocyte (E) and neutrophil (F) numbers of toxin-challenged mice were determined 10 hours after
toxin injection. Each bar represents the average of four mice in each group and the error bars represent the standard deviation. Asterisks (*) and
crosses ({) indicate a significant difference (Student’s t-test p,0.005 and p,0.05 respectively) relative to untreated mice.
doi:10.1371/journal.pone.0021457.g002
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conclusions presented in a previous report that injecting Stx2 and
LPS caused renal histopathology similar to that observed in
human HUS patients [9], thrombosis was not observed in our
Stx2/LPS-treated mice as revealed by both routine H&E and
PTAH staining. The main histologic changes were restricted to the
tubules and consisted of minimal to moderate tubular dilatation
and degeneration with occasional individual necrotic epithelial
cells and presence of necrotic debris within the lumen of dilated
tubules. The results of this analysis are summarized in Figure 2A
and representative images of WT and HuSAP+ mice that received
Stx2 and LPS are presented in Figure 2B/C. The location of this
damage is consistent with the cortical tubular epithelial cells
identified by Psotka et al. as the site of Gb3 expression and Stx2-
induced apoptosis [10]. Therefore, although LPS renders
HuSAP+ mice sensitive to Stx2 challenge, these mice do not
reproduce the histopathological alterations associated with HUS in
humans.
Effect of LPS on HuSAP-Stx2 Binding
HuSAP binds the majority of its ligands, perhaps including LPS
[35], in a Ca
2+-dependent manner at binding sites on the
pentamer’s ‘B’ face [6]. In contrast, HuSAP binds Stx2 in a
unique Ca
2+-independent manner at an unidentified binding site
[8]. Since we previously demonstrated that the Ca
2+-dependent
and Stx2 HuSAP binding sites likely overlap [36], we examined
whether LPS would competitively interfere with the ability of
HuSAP to neutralize Stx2. Using a solid-phase ELISA-type
binding assay we show that, even at the highest concentration
(100 mg/mL), LPS does not prevent the interaction between Stx2
and HuSAP either in the presence or absence of Ca
2+ (Figure 3A).
We also found that LPS had no effect on the ability of HuSAP to
neutralize Stx2 in a Vero cytotoxicity assay (Figure 3B), even in the
presence of other serum proteins that may be required for the
interaction between HuSAP and LPS (Figure 3C) [37,38].
Therefore LPS did not appear to directly prevent HuSAP binding
to Stx2.
Sugatani et al. previously reported that LPS reduces the
minimum lethal dose of Stx2 in mice, but this observation has
not been reproduced by others [23,39]. Increased sensitivity to
Stx2 independent of HuSAP+, as indicated by a lower minimum
lethal dose in WT mice, could provide a possible explanation for
the observed increased sensitivity to Stx2 in HuSAP+ mice. We
therefore assessed the sensitivity of WT mice to a dose range of
Stx2 with and without LPS treatment. As indicated by the data
presented in Figure 4, no difference was found between the
proportion of WT mice ultimately surviving a challenge of 63 pg/
g BW Stx2 injected with or without LPS. However, at this dose of
Stx2, co-administering LPS resulted in a shorter survival time
(compare dashed and solid red lines Figure 4, Log Rank test
p,0.001) with the average survival time being 70.3+/216.9 h
when Stx2 was injected with LPS compared to 102.7+/213.3 h
without LPS. Stx2 in combination with LPS therefore causes more
rapid pathological changes than Stx2 alone.
Expression of immune response genes in Stx2/LPS-
treated mice
To better understand the specific contribution of LPS to Stx2-
mediated pathogenesis in HuSAP+ mice, we used qPCR to
evaluate changes in immune response gene expression in renal
tissue obtained at 2 and 48 h from HuSAP+ and WT mice
challenged with Stx2 in the presence and absence of LPS. As an
indicator of the systemic immune response, we also determined the
serum concentrations of IL-6. The resulting data are summarized
in Figures 5 and 6 and Table S2. A profound pro-inflammatory
response was detected in the renal tissue immediately (2 hours)
following a combined injection of Stx2 and LPS. An extremely
high serum concentration of IL-6, an acute phase reactant and
pro-inflammatory cytokine, was detected (Figure 5) and IL-6 gene
expression in renal tissue increased a minimum of 5000 to 7000-
fold. Another mediator of systemic inflammation, tissue necrosis
factor a (TNFa), exhibited a more modest up-regulation (15 to 20-
fold) in the kidneys of challenged mice compared to untreated
animals. These changes were associated with a substantial increase
in the renal expression of several other inflammatory genes.
Expression of the neutrophil chemoattractant genes, CXCL1/KC
and CXCL2/MIP2 (macrophage inflammatory protein 2),
increased 800 to 1000-fold and 2200 to 2700-fold respectively
(Figure 6A). CXCL1 and CXCL2, were recently shown to be
essential for neutrophil recruitment which is key to acute renal
failure developing in Stx2-challenged LPS-treated mice [24].
More moderate increases in immune response gene expression
were observed for other inflammatory mediators such as CCL2/
MCP-1 (monocyte-chemoattractant protein, 170 to 230-fold) and
CCL5/RANTES (12 to 16-fold), both monocyte chemoattractants
(Figure 6A). Expression of both these chemokines was also shown
to be essential for macrophage recruitment to the kidney in Stx2-
challenged LPS-treated mice and apparently play a major role in
the observed renal damage [22]. Finally, although histopatholog-
ical examination (Figure 2B/C) did not reveal any signs of fibrin
deposition or thrombosis formation in the kidneys of these mice,
we did observe a substantial increase in expression of the
plasminogen activator inhibitor 1 gene (PAI-1, 70 to 100-fold), a
major inhibitor of fibrinolysis pathways, which could result in a
greater deposition of fibrin-clots throughout the body. Expression
of several other genes (including VCAM-1, tissue factor (TF), Gb3
synthase and others) was also studied, and the resulting data are
summarized in Table S2.
Importantly, changes in gene expression observed 2 h following
toxin injection appeared to be exclusively mediated by LPS
because, after 2 h, we detected no increase in gene expression
above baseline in animals after injecting Stx2 alone (data not
shown). Since none of the mice treated with LPS alone succumbed
whereas all WT mice treated with Stx2 did, the early expression of
pro-inflammatory factors does not correlate with morbidity. In
addition, we observed no significant difference at 2 h between
immune response gene expression in WT relative to HuSAP+
mice, presumably because the response was mediated exclusively
by LPS and providing evidence that HuSAP does not antagonize
LPS activity in vivo, despite previous reports indicating that it does
[35].
After 48 hours, no IL-6 was detected in the serum of Stx2- and
LPS-challenged mice (Figure 5) and only a mild up-regulation in
kidney IL-6 expression was observed (approximately 0.25% of the
expression measured at 2 hours). For the majority of inflammatory
genes, the magnitude of expression at 48 h was substantially
reduced relative to the 2 h values (note the change in y-axis scale
in Figure 6B compared to 6A). The only exception was TNFa
expression, which remained relatively constant at 2 and 48 hours.
Notably, the increased TNFa gene expression at 48 hours
appeared to be mediated almost exclusively by Stx2 (Figure 6C/
D). Moderate up-regulation of the IL-6 (8.4-fold+/21.6), CXCL1
(20.3-fold+/23.2), and CXCL2 (57.9-fold+/27.3) genes was
observed in WT mice injected with Stx2 alone. Nearly identical
changes (IL-6 [14.3-fold+/23.3], CXCL1 [26.3-fold+/220.3],
and CXCL2 [90.2-fold+/284.1]) were observed in WT mice
injected with both Stx2 and LPS (Figure 6B). Stx2 alone also
caused small, but significant, up-regulation of CCL5 and PAI-1
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21457Figure 3. Effect of LPS on HuSAP-Stx2 interaction. A. The ability of HuSAP to bind to Stx2-coated EIA plates was determined in the presence of
increasing concentrations of LPS. The assay was performed in the presence (TC buffer - dashed line) or absence (TN buffer - solid line)o fC a
2+. The
error bars represent the standard deviation about the means of three independent observations. B. Alternatively, this was assessed using the Vero-
cytotoxicity assay. HuSAP at a constant concentration of 20 mg/mL was incubated with serial dilutions of LPS prior to the addition of Stx2 at a
constant concentration of 2.5 ng/mL (filled black squares) with subsequent addition to confluent Vero cell monolayers. For comparison, Stx2 at a
constant concentration of 2.5 ng/mL was also incubated with serial dilutions of HuSAP (open diamonds) alone before adding the mixtures to
confluent Vero cell monolayers. The highest concentration of HuSAP tested in these serial dilutions was 20 mg/mL. Vero cell survival was assessed
after 72 h by recording absorbance at 620 nm. The x-axis refers to the concentration of HuSAP (open diamonds) or LPS (black squares) C. To ensure
that LPS did not bind HuSAP in complex with additional serum proteins, 100 mg/mL of LPS was pre-incubated for 30 minutes with serial dilutions of
human serum (containing HuSAP) prior to adding Stx2 and subsequent addition to Vero cells. The error bars represent the standard deviation about
the means of three independent observations.
doi:10.1371/journal.pone.0021457.g003
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21457Figure 4. Effect of LPS on sensitivity to Stx2 in WT mice. WT mice were IP injected with 200 pg/g (black lines), 63 pg/g (red lines), 20 pg/g
(green lines), or 6.3 pg/g BW (blue lines) of Stx2 in the presence (solid lines) or absence (dashed lines) of 300 ng/g BW LPS and survival was monitored
for seven days. The number of animals in each group is listed beside each label.
doi:10.1371/journal.pone.0021457.g004
Figure 5. Systemic cytokine response to Stx2 and LPS. The presence of the pro-inflammatory cytokine IL-6 in the serum of mice challenged
with 225 pg/g BW Stx2 and 300 ng/g BW LPS, 225 pg/g Stx2 alone or 300 ng/g LPS alone was quantified using a capture-ELISA technique (BD IL-6
OptEIA). Cytokine production in WT (A) and HuSAP+ (B) mice was compared and the immediate (2 hours) and delayed (48 hours) response was
measured. The error bars represent the standard deviation about the means of three independent observations for three individual mice. Asterisks (*)
denote a statistically significant (Student’s t-test p,0.005) difference relative to WT/NT (A) or HuSAP+/NT (B).
doi:10.1371/journal.pone.0021457.g005
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21457Figure 6. Inflammatory gene expression in kidneys of mice challenged with Stx2 and LPS. WT (black bars) and HuSAP+ (white bars) mice
were challenged with 225 pg/g BW Stx2 and 300 ng/g BW LPS (A, B), 225 pg/g Stx2 alone (C) or 300 ng/g LPS alone (D). Mice were euthanized at
2 hours (A) or 48 hours (B, C, D) after toxin injection for renal gene expression analysis. Error bars represent standard deviation between mice in the
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21457gene expression (Figure 6C). At 48 h, we detected almost no
changes in gene expression in mice injected with LPS alone
relative to untreated mice (Figure 6D). Importantly, the 48 h
profile of immune response gene expression induced by Stx2 alone
allowed us to detect differences which were consistent with the
survival of WT and HuSAP+ mice. Significant differences in
TNFa (64.66% less expression, p,0.05, Student’s t-test), CXCL1
(74.15% less expression, p,0.05, Student’s t-test), CXCL2 (71.3%
less expression, p,0.05, Student’s t-test), and CCL5 (49.4% less
expression, p,0.05, Student’s t-test) gene expression were
observed between HuSAP+ mice relative to their WT litter-mates
in response to Stx2 alone (Figure 6C). This reduced expression of
these inflammatory genes is associated with the survival of
HuSAP+ mice following challenge by Stx2 alone (Figure 1) and
therefore strongly suggests that increased expression of these four
genes is essential for mediating the acute renal failure and
mortality observed in WT mice following a challenge of Stx2
alone.
Of these genes, administering LPS alone caused significant up-
regulation of only CCL5 (2.61-fold+/20.56, Student’s t-test
p=0.048) at 48 h and no significant up-regulation of CXCL1
(1.52-fold+/20.49) or CXCL2 (1.47-fold+/20.44) gene expres-
sion. Despite the observation that LPS by itself had no apparent
effect on gene expression, it appeared to enhance inflammatory
gene expression induced by Stx2 in HuSAP+ mice. For each of
these genes, injecting Stx2 combined with LPS resulted in an
identical up-regulation of inflammatory gene expression in
HuSAP+ relative to WT mice (Figure 6B). This observation
further underscores the relationship between CXCL1, CXCL2
and CCL5 gene expression and survival since both HuSAP+ and
WT mice injected with Stx2 and LPS exhibited enhanced
expression of these three genes after 48 h and ultimately
succumbed (Figure 1).
Inhibition of Immune Response
We next tested two anti-inflammatory compounds for their
ability to provide therapeutic benefit in LPS-sensitized Stx2-
treated HuSAP+ mice. The two agents were selected for their
indirect (dexamethasone) and combined direct/indirect (LL-37)
inhibition of the effects of LPS. As a result of these differences in
their mode of action, the two agents had distinct effects on the
inflammatory response initiated by Stx2 and LPS in HuSAP+
mice (Figures 7 and 8). Except for TF, LL-37 inhibited the 2 h
response of all the other inflammatory genes by 63 to 97%
(Figure 8A). The LL-37 treatment also resulted in a reduction in
the serum concentration of IL-6 to a sub-detectable amount
(Figure 7). In contrast, DEX had little impact on the 2 h immune
response, significantly reducing only the expression of TNFa,
PAI1, and TF (Figure 8A) and the serum concentration of IL-6
(Figure 7). For CXCL1, DEX treatment caused a significant
increase in gene expression after 2 h. This trend, however, was
reversed at 48 h. Despite the profound reduction in the immediate
inflammatory response, LL-37 failed to reduce the expression of
any of the genes after 48 h, with the exception of VCAM1
(Figure 8B). Conversely, and despite its minimal effect on the
immediate response, DEX treatment significantly reduced the
Figure 7. Systemic cytokine response in HuSAP+ mice to Stx2 and LPS in the presence of inhibitor. HuSAP+ mice were challenged with
225 pg/g BW Stx2 and 300 ng/g BW LPS alone, admixed with 0.5 mg/g BW antimicrobial peptide LL-37 or 30 minutes after IP injection of 2.5 mg/g BW
dexamethasone (DEX). The immediate (2 hours) and delayed (48 hours) concentration of IL-6 was monitored. The error bars represent the standard
deviation about the means of three independent observations for three individual mice. Asterisks (*) denote a statistically significant difference
relative to mice treated with Stx2/LPS in the absence of inhibitor at the same time post-toxin injection (Student’s t-test p,0.005).
doi:10.1371/journal.pone.0021457.g007
same group (n=3). Asterisks (*) in panel C (Stx2 alone) indicate a statistically significant difference in gene expression in HuSAP+ mice relative to
similarly treated WT mice (compare white and black bars, Student’s t-test p,0.05). No statistically significant differences between HuSAP+ and WT
mice were detected in the basal expression of any gene. For clarity, expression data are not presented for mice treated with Stx2 alone after 2 hours
(no statistically significant increase in expression of any genes relative to untreated animals) and LPS alone after 2 hours (no statistically significant
differences relative to Stx2/LPS treatment).
doi:10.1371/journal.pone.0021457.g006
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35 to 85% after 48 hours (Figure 8B). CXCL2, CCL5, and TNFa
were also reduced in HuSAP+ mice (relative to WT) 48 hours after
Stx2 treatment (Figure 6C) and therefore may be crucial for the
inflammatory pathology leading to acute renal failure.
The well-defined differences in the effects of LL-37 and DEX on
the immune response allowed us to relate specific changes in gene
expression to survival in LPS-sensitized Stx2-treated mice. As
indicated by the data presented in Figure 9, only DEX protected
HuSAP+ mice challenged with the combination of Stx2 and LPS
(compare red and black lines Figure 9, Log Rank test p=0.048).
In contrast to DEX, LL-37 treatment failed to provide any
protective benefit (compare dashed blue and black lines Figure 9),
even at an extremely high dose (5 mg/g BW, solid blue line,
Figure 9). Despite the fact that LL-37 drastically reduced the
serum cytokine concentration (Figure 7) and inhibited the strong
up-regulation of inflammatory genes that was induced by LPS in
the kidneys 2 h after toxin injection (Figure 8), it had no effect on
mouse survival. This again emphasized the importance of
sustained as opposed to acute inflammation in the kidneys,
regardless of the magnitude of differences in gene expression.
Similar to the HuSAP-mediated protection, decreased sensitivity
to toxin in the presence of DEX was associated with the renal
production of chemokines of the CXC and CC families, as well as
the systemic inflammatory mediator TNFa, 48 h after toxin
injection.
Discussion
The loss of intestinal barrier function during EHEC infection is
thought to contribute to direct entry of Stx into the circulation.
This would presumably also allow entry of bacterial endotoxin into
the circulation, although there is limited evidence this occurs
following EHEC infection. LPS has been detected in the serum of
HUS patients following S. dystenteriae 1 infection, but not EHEC
infection [40,41]. In one study, O157 LPS was detected on the
surface of platelets in EHEC-infected HUS patients, but not in
patients that did not develop HUS [42]. Circulating antibodies
Figure 8. Inflammatory gene expression in kidneys of HuSAP+ mice challenged with Stx2 and LPS in the presence of inhibitor.
HuSAP+ mice were challenged with 225 pg/g BW Stx2 and 300 ng/g BW LPS alone (black bars), admixed with 0.5 mg/g BW antimicrobial peptide LL-
37 (white bars) or 30 minutes after subcutaneous injection of 2.5 mg/g BW dexamethasone (grey bars). Mice were euthanized at 2 hours (A)o r
48 hours (B) after toxin injection for renal gene expression analysis. Fold expression was normalized to the no treatment group (not shown) and the
data are presented as relative (%) to the gene expression observed in the Stx2/LPS group. Error bars represent standard deviation between mice in
the same group (n=3). Asterisks (*) indicate a statistically significant difference in gene expression compared to mice treated with Stx2/LPS without
inhibitor (black bars) at the same time post-toxin injection (Student’s t-test p,0.05).
doi:10.1371/journal.pone.0021457.g008
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serum LPS binding protein (LBP) concentrations are increased
[43,44,45]. The simple presence of antibodies to LPS in
circulation does not predict progression to HUS in EHEC-
infected patients [46], but these studies all suggest that at least
some LPS has entered the circulation in these subjects. In some of
the more severe cases of HUS preceded by EHEC infection,
subjects were observed to exhibit many of the clinical signs
associated with septic shock, suggesting severe endotoxemia [47].
There is abundant evidence that an inflammatory response occurs
in patients following EHEC infection which could be the result of
a mild endotoxemia. The evidence presented herein suggests that
HuSAP is unable to prevent renal damage in mice in the presence
of a prolonged inflammatory response.
The role LPS plays in HUS has not been clearly established, in
part because of apparent differences in its role in various animal
models. In the present study we demonstrate that LPS accelerates the
fatal pathological process initiated by Stx2 in mice (Figure 4). Several
studies have reported similar results although in certain animal
models, LPS is able to both enhance and prevent Stx toxicity [48].
For example, Ikeda et al. previously reported that co-administering
LPS with Stx2 caused haematological and histological alterations in
mice consistent with HUS but when LPS was injected 24 hours
before Stx2, neither of these effects were observed [49]. LPS is
apparently protective when injected 18–96 hours before Stx, but not
when injected within one hour of Stx or after Stx [34,39,49]. These
differences correlate with the occurrence of pro-inflammatory
cytokines (early response) and anti-inflammatory cytokines (late
response)incirculationafterLPSinjectionand,asaresult,ithasbeen
proposed that the intensity and duration of these responses might
explain differences in the severity of the symptoms [34]. We now
show, however, that reducing the pro-inflammatory response
(Figure7 and 8A)which occursimmediatelyafterStx2/LPSinjection
using LL-37 had no impact on the ultimate survival outcome
(Figure 9). In contrast, inhibition of the sustained pro-inflammatory
response by HuSAP or DEX (Figures 5 and 7) was protective.
DEX protection was specifically associated with a reduced
expression of CXC and CC-family chemokines, which are
responsible for recruiting neutrophils and macrophages to
inflamed tissues. Antibody neutralization of these chemokines
was previously shown to limit recruitment of inflammatory cells to
the kidneys following Stx2 and LPS challenge and thereby lessen
renal damage, but there was no survival benefit to separately
blocking each family [22,24]. Reducing both CC and CXC
chemokine families simultaneously, which was achieved herein,
may therefore be necessary for protection. The additional impact
of reducing TNFa expression may also play a significant role in
protection since TNFa has been demonstrated to up-regulate
endothelial cell Gb3 expression, increase Stx in vitro cytotoxicity,
and participate in TF up-regulation by Stx, in addition to its
numerous pro-inflammatory effects [50,51,52]. Recently, TNFa
was implicated by Lentz et al. as a key mediator of renal tubule
epithelial cell apoptosis, renal failure and lethality following Stx1
intoxication [53]. Notably, TNFa expression is localized to only
the kidneys in mice challenged with Stx and high concentrations
are detected in the urine, as opposed to the serum, of children in
the acute phase of EHEC-associated HUS, both of which suggest
that TNFa’s primary role is in mediating the kidney-specific
inflammatory response [17,54].
Although we have not extensively explored mechanisms of HUS
coagulopathy in the current report, it is possible that the primary
action of LPS is to induce a pro-thrombotic state. Stahl and
colleagues recently reported that O157 LPS binds and activates
human and murine platelets [42] and that Stx2 and E. coli LPS
synergize to produce monocyte-platelet and neutrophil-platelet
aggregates and stimulate tissue factor (TF) release into plasma
[55]. Our data also suggest a role for the coagulation cascade in
pathogenesis, since Stx2/LPS induce renal expression of plasmin-
ogen-activator inhibitor 1 (PAI-1) and TF (Figure 6 and Table S2)
and repression of these genes is associated with survival. TF up-
regulation at 48 hours is significantly reduced in HuSAP+ relative
to WT mice (Student’s t-test p=0.02, Table S2), and DEX inhibits
Figure 9. Survival of HuSAP+ mice challenged with Stx2 and LPS in the presence of inhibitor. HuSAP+ mice were challenged with
225 pg/g BW Stx2 and 300 ng/g BW LPS alone (black line), admixed with 0.5 mg/g BW antimicrobial peptide LL-37 (blue dashed line), admixed with
5.0 mg/g BW LL-37 (solid blue line) or 30 minutes after subcutaneous injection of 2.5 mg/g BW dexamethasone (solid red line). HuSAP+ mice
challenged with 225 pg/g BW Stx2 alone were included for comparison (grey dashed line). The number of animals in each group is listed beside each
label. The asterisks (*) denotes that the differences in survival between HuSAP+ mice treated with Stx2/LPS without inhibitor and those treated with
Stx2/LPS and dexamethasone was statistically significant (Log Rank test p=0.048).
doi:10.1371/journal.pone.0021457.g009
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48 hours after toxin injection (Figure 8).
Since HuSAP effectively neutralizes Stx2 in the absence of LPS,
we propose that neutralizing the effects of LPS may be an effective
therapeutic approach in EHEC-infected patients who already
possess HuSAP in their serum [8]. Herein we investigated two
possible LPS-inhibitors that act through two diverse mechanisms.
Human cathelicidin-derived cationic antimicrobial peptide LL-37
modulates the LPS-induced inflammatory response and is capable
of preventing endotoxemia/sepsis in a variety of animal models,
including the mouse [56,57]. It does so via a complex mechanism
involving both direct and indirect intervention. LL-37 blocks LPS
from binding LPS-binding protein (LBP) and prevents its
subsequent interaction with both the soluble and membrane-
bound form of CD14 on the surface of several cell types thereby
preventing Toll-like receptor activation [58]. As well, LL-37 alters
intracellular signal transduction pathways, selectively modulates
pro- and anti-inflammatory gene transcription and is thought to
influence protein translation or stabilization [31].
DEX, in contrast, is an anti-inflammatory drug of the synthetic
glucocorticoid class and is used extensively in clinical practice in
managing inflammatory and autoimmune conditions [59,60].
Although the exact mechanism of action is unknown, DEX acts on
a variety of immune cell types, including macrophages, neutrophils
and epithelial cells, and suppresses the production of pro-
inflammatory cytokines [32,33]. Specifically, DEX protects mice
against high dose-LPS mediated lethality by reducing TNFa and
IL-6 expression through a variety of intracellular signalling
pathways [33]. In addition, DEX suppression of the inflammatory
response enhances the survival of mice challenged with Stx2 alone
[34,61,62]. These studies and ours suggest the potential for DEX
as a therapeutic agent in HUS. In this regard, DEX is an effective
treatment for two similar conditions, idiopathic thrombocytopenic
purpura (ITP) and non-EHEC-associated thrombotic thrombocy-
topenic purpura (TTP), and is therefore worth consideration as
part of the management of EHEC-infected HUS patients [59,63].
Supporting Information
Table S1 The primers used for amplification and
references for each selected gene are summarized.
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Table S2 Additional gene expression in kidneys of mice
challenged with Stx2 and LPS. As in Figure 6, WT and
HuSAP+ mice were challenged with 225 pg/g BW Stx2 and
300 ng/g BW LPS, 225 pg/g Stx2 alone or 300 ng/g LPS alone.
Mice were euthanized at 2 hours or 48 hours after toxin injection
for renal gene expression analysis. Asterisks (*) indicate a
statistically significant difference in gene expression in HuSAP+
mice relative to similarly treated WT mice (Student’s t-test
p,0.05). No statistically significant differences between HuSAP+
and WT mice were detected in the basal expression of any gene.
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